Houston, TX -- (SBWIRE) -- 12/11/2012 -- Amarin Corporation plc (ADR) (NASDAQ:AMRN) is currently trading at $8.94, 4.28% lower. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA).